Details for Patent: 11,850,225
✉ Email this page to a colleague
Which drugs does patent 11,850,225 protect, and when does it expire?
Patent 11,850,225 protects LYVISPAH and is included in one NDA.
This patent has one patent family member in one country.
Drugs Protected by US Patent 11,850,225
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal | LYVISPAH | baclofen | GRANULES;ORAL | 215422-001 | Nov 22, 2021 | RX | Yes | No | 11,850,225 | ⤷ Subscribe | Y | TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS, PARTICULARLY FOR THE RELIEF OF FLEXOR SPASMS AND CONCOMITANT PAIN, CLONUS, AND MUSCULAR RIGIDITY | ⤷ Subscribe | |||
| Amneal | LYVISPAH | baclofen | GRANULES;ORAL | 215422-001 | Nov 22, 2021 | RX | Yes | No | 11,850,225 | ⤷ Subscribe | Y | TREATMENT OF SPASTICITY RESULTING FROM SPINAL CORD INJURIES AND OTHER SPINAL CORD DISEASES | ⤷ Subscribe | |||
| Amneal | LYVISPAH | baclofen | GRANULES;ORAL | 215422-002 | Nov 22, 2021 | RX | Yes | No | 11,850,225 | ⤷ Subscribe | Y | TREATMENT OF SPASTICITY RESULTING FROM SPINAL CORD INJURIES AND OTHER SPINAL CORD DISEASES | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,850,225
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2023055457 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
